Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China

BACKGROUND: To compare the overall survival (OS) of patients with advanced lung adenocarcinoma in China before and after the approved use of gefitinib, and analyze clinical factors that may affect OS. METHODS: Clinical data of 558 patients with advanced lung adenocarcinoma who received chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yu-Tao, Hao, Xue-Zhi, Li, Jun-Ling, Hu, Xing-Sheng, Wang, Yan, Wang, Zi-Ping, Wang, Hong-Yu, Wang, Bin, Han, Xiao-Hong, Zhang, Xiang-Ru, Shi, Yuan-Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567010/
https://www.ncbi.nlm.nih.gov/pubmed/26445613
http://dx.doi.org/10.1111/1759-7714.12267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567010/
https://www.ncbi.nlm.nih.gov/pubmed/26445613
http://dx.doi.org/10.1111/1759-7714.12267

Ejemplares similares